Fucoidan


Fucoidan

What’s Fucoidan

FUCOIDAN GOLD

 

180 tablets

【FUCOIDAN GOLD】

 

FUCOIDAN MIX UKON

 

180 tablets

【FUCOIDAN MIX UKON】

 

Features

  • Raw material of Fucoidan is Okinawa okamuranus only
  • High purity of Okinawa okamuranus(Over 80% contents in powder)
  • Small and easy to drink tablet( Expiration date: 2 years )

Comparison with other products.

  • Fucoidan is a general term for a water-soluble polysaccharide
  • Raw materials of fucoidan are from Mozuku, kelp, seaweed
  • Each material has a different structural formula
  • Each manufacturer has different procedure of extractions and production
  • For those reasons, it is not impossible to compare the “mg” simply

Our strengths

  • In all of those products, we only have many evidences.
  • Especially the paper about liver cancer is used by our products.
  • We have the data for “Gastric ulcer”. (In Japanese)
  • It’s enough for  gastric ulcer to take 100mg/day.
  • We recommend 100-300mg / day. (Absorption rate is different for different people)
  • Our products (50mg/ tablets) are easy to control for intake per day.

FAQ

1.The meaning “Anti-blood clotting action is very weak.”

First fucoidan is included in the category of “sulfated polysaccharide”.
Chondroitin sulfate and heparin are in the same sulfated polysaccharides.
With respect to blood clotting, heparin is used as a drug of anti-blood clotting.
Since fucoidan also the same category as heparin, we have implemented the test of blood clotting action.
The result is that the anti-blood clotting effect is weak.
Therefore, in the case of fucoidan is in contact with the bleeding ulcers part, if it has strong anti-blood clotting action, we need to check the side effect of increasing the bleeding.

2.Is it contained more than 40mg fucoidan if 50mg of “purity of 80% or more”?

That’s right.
When you want to 100mg formulation of Fucoidan, it will be referred to 100mg ÷ 0.8 = 125mg.
But each Fucoidan still has a difference of structural formula.

Fucoidan included in OKINAWA okamuranus

Fucoidan is a sulfated polysaccharide that is included most in Okinawa mozuku. Okinawa okamuranus fucoidan has revealed a variety of physiological activities, such as gastric ulcer preventive effect, intestinal regulation action immune and an activating action. In addition, the other derived from seaweed fucoidan has a strong anti-blood clotting action but Okinawa okamuranus fucoidan has a very weak feature.
It does not contain other polysaccharides, such as alginic acid in Okinawa mozuku. Therefore, it is possible to produce high-purity fucoidan.

Fucoidan Effectiveness

      1. Activation of cell immune system

Fucoidan derive apoptosis strongly for lymphocyte and leukemia cell.

      1. The biological properties of Fucoidan as either immuno-stimulators or apoptosis inducers may be dependent on molecular weight, or differences in the components of polysaccharides.(1)

      2. Anti-inflammatory effect

The levels of IL-6 mRNA in colonic epithelial cells was lower in colitis-induced Balb / c mice fed Cladosiphon fucoidan than those fed a standard diet.

    1. Fucoidan improves murine chronic colitis by down-regulating
    1. the synthesis of IL-6 in the colonic epithelial cells.
      1. Fucoidan derived from C. o. Tokida may be useful as a dietary substance for the patients with inflammatory bowel disease.(2)

      2. Gastritis prevention

Cladosiphon Fucoidan is a safe substance with potential for gastric protection and may deserve particular attention as a safe agent that can prevent H. pylori infection and reduce the risk of associated gastric cancer.(3.4)

      1. Daily intake of Fucoidan has useful to the prevention and eradication of H. pylori and non-ulcer dyspepsia.(5)

      2. Improvement for gastric motility (6)
      3. Anti tumor effect

Fucoidan exhibits antitumor activity toward Huh7 cells through the downregulation of CXCL12 expression and has a potential therapeutic effect on HCC. (7.8)

    1. Fucoidan is a potentially useful therapeutic agent for patients with ATL.(9)
    1. The oversulfated fucoidan induced apoptosis via caspase-3 and -7 activation-dependent pathway.(10)

    2. Anti-fibrotic effect

As anti-fibrotic mechanism of Fucoidan, TGFβ1 suppression, suggesting that through inhibition and free radical scavenging action CXCL12.(11)

    1. Anti-obesity effect(12)

Fucoidan controls lipolysis depending on concentration. It significantly declines the contents of neutral fat.

    1. Anti-blood clotting activity(13)

Fucoidan has a heparin-like bioactive, anticoagulant activity and antithrombotic effect.

References


(1) Biological Properties of Fucoidans Differing in Molecular Weight and Composition : Effects on Lymphocyte Proliferation and Immunological Function
(2)Fucoidan derived from Cladosiphon okamuranus tokidaameliorates murine chronic colitis through the down-regulation of interleukin-6 production on colonic epithelial cells.
(3) Properties of fucoidan from Cladosiphon okamuranus tokida in gastricmucosal protection.
(4)Preventive effect of Cladosiphon fucoidan against Helicobacter pylori infection in Mongolian gerbils.
(5)Effect of Fucoidan Containing Tea on the Eradication of H.pylori and Non-ulcer Dyspepsia
(6) Study of Fucoidan from Cladosiphon
(7)Inhibitory effect of fucoidan on Huh7 hepatoma cells hrough downregulation of CXCL12.
(8)Effect of fucoidan on the biotinidase kinetics in human hepatocellular carcinoma.
(9)Fucoidan extracted from Cladosiphon Okamuranus TOKIDA nduces apoptosis of human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells.
(10)Anti-proliferative activity of oversulfated fucoidan from commercially cultured ladosiphon okamuranus TOKIDA in U937 cells.
(11)Attenuation of N-nitrosodiethylamine -induced liver fibrosis by high-molecular-weight fucoidan derived from Cladosiphon okamuranus.
(12)Anti-obesity effect of Okinawa Mozuku derived from fucoidan.
(13)A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds.

Topics

Effects of Fucoidan on Hepatitis C Virus

Hepatitis C Virus Has Infected 4.5 Million Vietnamese

TheestimatedglobalnumberofpeoplewhoareinfectedwithhepatitisCvirus(HCV)is170million,andapproximately4.5millionVietnamesearesufferingfromHCV-relateddiseases.Thefirstlinetreatmentforchronichepatitis(CVC)includesthecombinationofpegylateda-interferon(IFN)andabroadspectrumantiviraldrug.However,theHCVeradiationsuccessrateusingthiscombinationtherapyvariesbetweenthegenotypes,andantiviraltreatmentsometimescausesseriousadversereactions.Therefore,itisdesirabletoestablishanewtreatmentmodality.
Accordingtothereportin2012writtenbyProfessorNaokiMoriandhisgroupattheUniversityoftheRyukyus,itwasdemonstratedthatcladosiphonokamuranusTokida,whichiscultivatedinOkinawa,Japan,hassignificantinhibitoryeffectsonHCV.

FucoidanInhibited the Expression of HCV Replication in Vitro

Toevaluateeffectsoffucoidan,HCVcellswereculturedinthepresenceoffucoidan.
ItwasfoundthatfucoidandosedependentlyinhibitedtheexpressionofHCVreplication.Moreover,theresultsuggestedthatfucidandidnothavecytotoxiceffects(Figure1).

Beneficial Effects of Fucoidanin Patients with Chronic HCV Infection

Fucoidan(830mg/aday,oral)wasadministeredto15patientswithchronicliverdiseases(9patientswithchronichepatitisC,4patientswithlivercirrhosis,and2patientswithbothcirrhosisandhepatocellularcarcinoma)for12months.ItwasobservedthatHCVRNAlevelsdecreasedsignificantlyat8th-10thmonthsofthetreatment(Figure2.A),buttheyincreasedatthe11thmonth.Althoughtheeffectsmightbetemporary,fucoidancertainlyinhibitedHCV.
SerumALTlevels,amarkerforliverdamage,weremeasuredfor12months(Figure2.B),andnoneofthepatientsshowedprogressionoflivercirrhosisorotherseriousadverseevents.
ThisexperimentdidnotshowthatfucoidaninhibitedHCVinthelongterm,butfucoidanmightbeeffectiveinthemanagementofHCV-relatedchronicliverdiseases.Sincetheresultsuggestedthesafetyofdailyoraladministrationoffucoidanfor12months,itisexpectedthatfucoidanwillbecomeavailableinthefutureforcontrollingliverdamage.

References

Beneficial effects of fucoidan in patients with chronic hepatitis C virus infection. Naoki Mori, Kazunori Nakasone, Koh Tomimori, Chie Ishikawa World J Gastroenterol 18(18): 2225-2230 (2012)

Fucoidan events in Vietnam

2017-05-13